drugset
drugset / Trial / NCT04464395

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

NCT04464395 ↗

Phase 1 Completed 30 enrolled Corvus Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients with a parallel non-randomized Control Arm for treatment with standard of care only.

Timeline

Start
2020-07-01
Primary completion
2021-03-01
Completion
2021-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MUPADOLIMAB Monoclonal antibody 0.3 mg/kg —
Subject MUPADOLIMAB Monoclonal antibody 1 mg/kg —
Subject MUPADOLIMAB Monoclonal antibody 3 mg/kg —
Subject MUPADOLIMAB Monoclonal antibody 5 mg/kg —

Indications

COVID-19